The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE: JNJ) has reached an agreement with the state of Texas to pay $158 million to settle all claims related to overcharging the state’s Medicaid program for the anti-psychotic drug Risperdal from 1994-2008. MarketWatch reports that the original plaintiff, his attorneys, the state of Texas, and the federal government will share the settlement amount.
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
Our top personal finance-related articles today. Your wallet will thank you later.
Top Gaining Stocks
Top Losing Stocks